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Immunosuppressive Treatment 
in Multhocal Motor Neuropathy 
Eva L. Feldman, MD, PhD, Mark B. Bromberg, MD, PhD, 
James W. Albers, MD, PhD, and Alan Pestronk, MD* 
We report the results of immunosuppressive treatments of 13 patients with rnultifocal motor neuropathy and elevated 
titers of serum antibodies to the GM1 ganglioside. All patients failed to respond to oral prednisone. There was no 
clinical response in 4 patients treated with plasma exchange. Nine patients received cyclophosphamide, with clinical 
improvement and fall in antibody titers in 8. In 3 patients, cyclophosphamide was discontinued with ensuing clinical 
relapse and rise in the titers of serum anti-GM1 antibodies. These patients provide further evidence for the efficacy 
of cyclophosphamide therapy in patients with multifocal motor neuropathy. 
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Lower motor neuron syndromes can be divided into 
clinical subsets based on the patterns of weakness, elec- 
trodiagnostic abnormalities, and serum antiglycolipid 
antibody activity [I]. One such syndrome, multifocal 
motor neuropathy (MMN), is characterized by distal, 
asymmetrical weakness and conduction block on motor 
but not sensory axons [ 1-41. High titers of serum anti- 
bodies to GM1 ganglioside are common in this syn- 
drome [I ,  2) and in acquired lower motor neuron syn- 
dromes in general 11, 5-91. 
Individual patient reports suggest that MMN may 
respond to immunotherapy [2). Cytotoxic medications 
such as cyclophosphamide may be useful in producing 
clinical improvement, that is, an increase in strength 
C2, 31. In this study, we report our retrospective expe- 
rience with the treatment of a series of 13 patients with 
a diagnosis of MMN. Our results show that prednisone 
treatment, even in high doses, is not often associated 
with clinical benefit in patients with MMN. In contrast, 
improvement in strength commonly occurs within 3 to 
6 months after institution of cyclophosphamide ther- 
apy. Further, there is usually a correlation between 
clinical improvement and reduction of titers of anti- 
GMl  antibodies. 
Patients and Methods 
Patients 
We studied the effects of immunosuppressive therapy in pa- 
tients with MMN defined by clinical, electrophysiological, 
and immunological criteria (see Results). The features of 9 of 
these patients (Patients 1, 2, 6, 7, 9-13) have been outlined 
previously [ 11. Three improved after cyclophosphamide ther- 
apy in that study. The patients with MMN reported here are 
all those examined and treated by us between January 1987 
and June 1990. 
Electrodiagnostic Studies 
Electrodiagnostic studies were performed under standard 
conditions with attention to maintenance of skin temperature 
above 32°C. Conduction block in motor nerves was defined 
as a reduction in the ratio of proximal-to-distal compound 
muscle action potential (CMAP) amplitude to <0.70 when 
the ratio of the proximal-to-distal negative peak duration was 
<1.15 [lo-121. Abnormal temporal dispersion with or with- 
out conduction block was considered present when the ratio 
of proximal-to-negative peak duration was > 1.15. Potential 
sites of nerve entrapment were taken into consideration 
when evaluating conduction block. 
Determination of Serum Antibodies 
Antibodies to gangliosides were assayed by enzyme-linked 
immunosorbent assay (ELISA) methodology as described 
previously [l]. Briefly, 400 ng of GM1 (Sigma Chemical, St 
Louis, MO) was adsorbed to wells of ELISA plates before 
the addition of test serums at dilutions of 1:50 to 1:100,000 
for 5 hours at 4°C. Horseradish peroxidase-linked specific 
goat anti-human IgM or IgG was then added overnight, and 
color was developed for approximately 30 minutes until a 
standard positive control reached an optical density (OD) 
of 1.0 at 450 nm. Serum ODs were determined and titers 
calculated from a linear range of dilutions. Titers of serum 
IgM agonist GM1 ganglioside 2 3 5 0  are more than 4 SDs 
above the mean value in panels of normal control subjects 
[13}. A spontaneous fall of more than 60% in titers of IgM 
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anti-GM1 antibodies occurs in less than 5% of untreated 
patients { 14). 
Quantitation of Motor Function 
Strength testing was quantitated using the Medical Research 
Council (MRC) rating scale. MRC values were determined 
on each side for the following six muscles: deltoids, biceps, 
interossei, iliopsoas, quadriceps, and anterior tibialis. A pa- 
tient was judged improved if strength increased in weak mus- 
cles of at least one extremity an average of one or more MRC 
grades. MRC values were also averaged for each patient, 
giving a strength index [hat could be followed over time. 
Selective Patient Reports 
Patient 6 
A 63-year-old woman presented in 1985 with a 10- 
year history of progressive weakness. Bilateral thumb 
weakness was followed 5 years later by left finger ex- 
tensor weakness, which progressed slowly to involve 
intrinsic hand muscles bilaterally. Neurological exami- 
nation revealed asymmetrical atrophy and weakness in 
the upper extremities with greater involvement dis- 
tally. Lower extremity strength was normal. Deep ten- 
don reflexes were preserved. Sensory examination was 
normal. She was treated for 3 years with oral predni- 
sone, up to 60 mg per day, but weakness progressed 
to include lower extremities and she became areflexic. 
Nine therapeutic plasma exchanges and intravenous 
methylprednisone (1 gm x 3 treatments) did not inter- 
rupt her decline. By the end of 1987, she was quadri- 
plegic and was begun on intravenous cyclophospha- 
mide (3 gm/M2), followed 1 month later by oral 
cyclophosphamide (2 mg/kg/day). Within 4 months she 
began to regain strength, and after 6 months was ambu- 
latory and had full use of her hands, at which time 
cyclophosphamide was discontinued. She remained 
stable for 1 year, but then noticed the return of thumb 
weakness. Oral cyclophosphamide ( 2  mglkg/day) was 
restarted and within 1 month her strength returned. 
Serum and urine immunofixation patterns and cere- 
brospinal fluid protein were normal. A sural nerve bi- 
opsy was normal. IgM anti-GM1 titer was 480 units 
before cyclophosphamide therapy and fell to 0 units 
over 15 months. As the antibody titer rose to 195 
units, she had an exacerbation, and as the titer fell to 68 
units with treatment, she went into remission. Sensory 
nerve conduction studies were normal. Motor nerve 
conduction studies showed conduction block with vary- 
ing degrees of abnormal temporal dispersion (Fig 1). 
Patient 5 
A 35-year-old man presented with 1.5 years of weak- 
ness first affecting the grip of his right hand, then weak- 
ness of his right arm and left leg. He had no sensory 
complaints. Neurological examination revealed atro- 
phy and weakness of the right hand and left leg. Re- 
Elbow - 
Median Nerve 
Fig 1. Median motor conduction study of Patient 6, demon- 
strating partial conduction block. The area d the median nerve 
vesponse on elbow stimulation is <30% of the response on wrist 
stimulation. 
flexes were present and normal in the left arm and left 
knee, but decreased in the right arm and were absent 
at the left ankle. Sensory examination was normal. The 
patient was begun on prednisone, 60 mg per day for 
3 months, but his weakness progressed. Intravenous 
cyclophosphamide (3 gm/M2), followed by oral cyclo- 
phosphamide (2 mglkglday), was started. Improvement 
in strength occurred by 6 weeks and he has returned 
to work. His neurological examination has remained 
normal while he takes oral cyclophosphamide. 
Serum and urine immunofixation patterns and cere- 
brospinal fluid protein were normal. Sural nerve biopsy 
was normal. IgM GM1 ganglioside titer was 398 units 
before cyclophosphamide therapy and fell to 50 units 
over 4 months. Sensory nerve conduction studies were 
normal. Motor nerve conduction studies showed con- 
duction block. 
Results 
The clinical and electrophysiological profiles of the 13 
patients are presented in Table 1. There were 9 men 
and 4 women, ages 30 to 66 years. All 13 patients had 
asymmetrical weakness, with prominent upper extrem- 
ity involvement and a normal sensory examination. Re- 
flexes were normal in 6 patients, decreased in 4 pa- 
tients, and absent in 3 patients. Duration of symptoms 
ranged from 1 to 20 years. Eight patients had normal 
motor nerve conduction velocities, and 5 had mild 
slowing. All 13 patients had normal sensory-evoked 
amplitudes and conduction velocities. The strikmg 
finding in each patient was prominent multifocal motor 
conduction block with varying degrees of abnormal 
temporal dispersion, especially in the upper extremi- 
ties (see Fig 1). Serum anti-GM1 antibody titers were 
high (2350) in each of the patients. 
All patients were treated with high-dose oral predni- 
sone, many for extended periods, with no clinical re- 
sponse. In the 4 patients treated with only prednisone 
(Patients 1-4) there was no consistent change in anti- 
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Table I .  Clinical and PbyJiological Profile 
Motor Conduction Studies 
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GM1 antibody titers. Titers increased in 2 patients and 
decreased in the 2 others. Four patients received 
plasma exchange without clinical benefit. 
Nine patients received intravenous and follow-up 
oral cyclophosphamide treatment [2], with the major 
side effects of mild leukopenia and alopecia. Eight 
showed clinical improvement of at least one full grade 
on the MRC scale during the first 2 to 5 months of 
treatment. This was usually paralleled by reduced se- 
rum GM1 antibody titers, which decreased to an aver- 
age of 67%) of initial levels (Table 2). The percent 
change in titer, and not the absolute level of titer, 
correlated with changes in clinical course. Three pa- 
tients relapsed after cyclophosphamide treatment was 
stopped. In all, anti-GMl titers had risen toward pre- 
treatment values. Two of these patients were retreated 
with cyclophosphamide with subsequent improvement 
in strength. 
Sequential electrophysiological studies were per- 
formed on Patient 6. The progression of weakness was 
related to a progressive decline in the CMAP am- 
plitude. The proximal/distal amplitude ratio was a 
poor predictor of strength because a disproportionate 
increase in the distal amplitude could result in a 
decreased ratio at a time that both amplitudes and 
strength were increasing (Fig 2). 
Discussion 
In this study, we followed the clinical status of 13 pa- 
tients with MMN who were treated with immunosup- 
pressive therapy. Our results suggest that prednisone 
is rarely an effective treatment for this syndrome. 
None of our patients with MMN improved during pe- 
riods of treatment with prednisone alone. The 4 pa- 
tients who were never treated with a cytotoxic medica- 
tion all showed slow, continued progression during the 
1 to 3 years of observation. The pattern of prednisone 
resistance of MMN is consistent with most reports of 
patients with asymmetrical motor neuropathy and mo- 
tor conduction block [Z, 31. 
In contrast to the lack of response to prednisone, 
cyclophosphamide treatment was associated with im- 
proved strength in 8 of 9 patients with MMN. Im- 
provement began in the 8 patients after 2 to 5 months 
of treatment. The eventual degree of increased 
strength in these patients was at least one MRC grade. 
One patient (Patient 6), who was initially quadriplegic, 
improved to normal strength in most muscle groups. 
In some patients, maintenance of immunosuppressive 
medications appeared necessary for continued control 
of the disease process. Three patients developed recur- 
rent weakness 6 to 12 months after cyclophosphamide 
treatment was discontinued. Two of these patients 
were restarted on cyclophosphamide with improve- 
ment of strength. Treatment with cytotoxic medica- 
tions has also been reported effective in other patients 
with lower motor neuron syndromes and high titers of 
anti-GM1 antibodies [1, 15, 161. 
These experiences suggest that cyclophosphamide 
treatment may be effective in inducing and maintaining 
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Table 2. Therapeutic Response Projle 
Change in MRC Scale" 
Anti-GM1 Titers Plasma Cytotoxic 
Patient Prednisoneb Exchange Medication Pre-Therapy During Therapy % Reduction Relapse 
- 114,250 60,800 47 . . .  1 0 (60 x 4 mo) - 
582 486 16 . . .  2 0 (60 x 3 mo) - - 
3 -1 (60 X 6 w k )  - - 14,360 19,040 - 33 . . .  
370 720 - 94 . . .  4 0 (50 X 1 yr) - - 
+ I  398 50 87  . . .  5 0 (60 x 3 mo) - 
6 - 1 (30 x 3 yr) 0 +3 458 0 100 198 
7 0 (60 x 4 mo) - + I  204,500 56,080 73 . . .  
+ I  2,205 2,048 7 . . .  8 0 (80 x 4 mo) - 
9 0 (80 X 5 mo) - + 2  1,490 102 93 606 
10 - 1 (100 x 6 mo) 0 + 2  3,880 908 76 . . .  
11 O(100 x 4 m o )  0 + 2  1,535 395 74 996 
12 0 (80 x 6 mo) 0 0 13,693 9,600 30 . . .  
13 0 (60 x 2 mo) - + I  1,570 - - . . .  
a - 1 indicates loss of at least one MRC grade; 0, no change in MRC grade; + 1 indicates improvement by 1 MRC grade, + 2 by 2 MRC grades, 
and + 3 by 3 MRC grades. 
bAverage dose of prednisone given on a daily basis. 
MRC = Medical Research Council. ( - )  Indicates patient did not receive therapy or anti-GM1 titer was not measured. 
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Fig 2. Relationship of changes in distal and pmximul ulnar 
newe motor-evoked amplitude and functional status during im- 
munosuppressive therapy in Patient 6. Arrow indicates initia- 
tion of cyclophosphamide treatment. (4)= Distal ulnar 
motor-ez~oked amplitude; (-n-) = proximal ulnav motor- 
evoked amplittlde; (-@--) = acierage MRC strength index. 
clinical remission of MMN. Spontaneous improvement 
is rare in patients with motor neuron disorders or mo- 
tor neuropathies that are progressive for more than 1 
year Tlf. The percentage of patients in our study who 
improved after cyclophosphamide treatment, 88% (8 
of 9 patients), is significantly greater (p < 0.001) than 
the 0% response to prednisone in the same patients. 
Overall, the clinical course was paralleled by changes 
in anti-GM1 antibody titers. These titers showed no 
consistent change during treatment with prednisone. 
Titers were reduced, however, by an average of 67% 
after cyclophosphamide therapy [14f. Most patients 
began to improve during the period when antibody 
titers fell below one-half of their initial levels. AH 4 
patients with improvement in strength of two or more 
MRC grades had a reduction in their anti-GM1 anti- 
body titers of 70% or more. Measurement of anti- 
GM1 antibody titers is probably useful, not only for 
diagnosing MMN, but also for monitoring necessary 
and sufficient treatment during a trial of cyclophos- 
phamide. 
Our results provide more evidence that MMN is an 
immune-mediated process. The disorder differs, how- 
ever, from typical chronic inflammatory demyelinating 
polyneuropathy (CIDP) { 17, 181. Patients with pre- 
dominantly motor forms of CIDP 119,201 usually have 
symmetrical weakness that involves proximal muscles 
early in the course of the disease. Although nerve con- 
duction studies in patients with CIDP may show evi- 
dence of conduction block, there is often evidence of 
more diffuse demyelination of both motor and sensory 
axons. Changes in CIDP that occur in only a minority 
of patients with MMN include slowing (<70% of nor- 
mal) of conduction velocities and prolonged distal la- 
tencies. A further difference between MMN and 
CIDP lies in their serum antibody reactivity. High ti- 
ters of IgM anti-GM1 antibodies are common in pa- 
tients with MMN, but rare in patients with CIDP 
[l]. A final contrast between the two disorders is 
their response to treatment. As has been reported 
for the overall population of patients with CIDP, 
those with motor CIDP usually demonstrate increased 
strength within a few months after treatment with 
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prednisone. This is clearly not the case for patients 
with MMN. 
In summary, our results provide further support for 
the effectiveness of cyclophosphamide therapy in pa- 
tients with MMN. Controlled trials would be useful to 
confirm this conclusion. Even if cyclophosphamide is 
efficacious, however, its toxicity limits the benefit: risk 
ratio, especially in patients with only mild disability. 
Trials of other medications with fewer side effects are 
also necessary. 
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